Please login to the form below

Not currently logged in
Email:
Password:

Intercept Pharma

This page shows the latest Intercept Pharma news and features for those working in and with pharma, biotech and healthcare.

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner. Intercept has presented further data backing the efficacy of Ocaliva in non-alcoholic steatohepatitis (NASH), but side effects are still making investors nervous. ... Intercept also reported new

Latest news

  • Liver specialist Genfit files $120m IPO on Nasdaq Liver specialist Genfit files $120m IPO on Nasdaq

    Shortly afterwards, Intercept Pharma reported somewhat mixed phase 3 data for its NASH drug obeticholic acid, although analysts suggested the data could still be enough to support an FDA approval.

  • Intercept NASH drug closes in on FDA approval Intercept NASH drug closes in on FDA approval

    Although the drug failed to meet secondary endpoint. Intercept looks like it could become the first biopharma company to get a drug for non-alcoholic steatohepatitis (NASH) approved for marketing, although ... Intercept’s trial enrolled mainly patients

  • Gilead NASH drug clears mid-stage trial, but rivals are looming Gilead NASH drug clears mid-stage trial, but rivals are looming

    Positive results to challenge Intercept in emerging disease area. Gilead has new data backing up its liver disease candidate GS-9674 in non-alcoholic steatohepatitis (NASH), tipped as one of the ... The new data shows Gilead’s drug is working as

  • Intercept hit hard as FDA issues Ocaliva safety notice Intercept hit hard as FDA issues Ocaliva safety notice

    Intercept Pharma has only had a few months to revel in its first product launch before a safety warning from the FDA knocked it back. ... Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in

  • Intercept gets EU nod for rare liver disease therapy Intercept gets EU nod for rare liver disease therapy

    Ocaliva approved as a combination treatment for primary biliary cholangitis. Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both sides of the ... Intercept launched Ocaliva in the US

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics